Plain-English translation of NCT07537491 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
The KIA-Korekt study is developing an artificial intelligence tool to help doctors predict which colorectal cancer patients are at higher risk for problems after surgery. The tool analyzes three types of medical information: pathology slides from your tumor, CT or MRI scans, and special staining of tumor tissue that shows immune cells. This information could help doctors better prepare you for surgery and monitor you more carefully afterward.
Even with modern surgery and care, many colorectal cancer patients experience serious complications after their operations, including infections, blood clots, and other problems. Existing risk prediction tools don't do a good job of identifying which patients are most at risk. This trial aims to create a better, more personalized prediction tool using artificial intelligence.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will allow the researchers to use your existing medical records, CT or MRI scans, and tumor tissue samples that were already taken during your cancer diagnosis and treatment. The study involves both past patient data (from 2011–2021) and new patients enrolling between 2026–2028. You won't need to have additional surgery or procedures; the researchers will analyze information that's already part of your care.
AI-generated summary from trial data · Aug 11, 2026 · Not medical advice
Germany